Suchergebnisse - "Yamada, Tadaaki"

PubPharm (282)

51

Corrigendum to "A real-world study on the safety of the extended dosing schedule for nivolumab and pembrolizumab in patients with solid tumors" [Int. Immunopharmacol. 108 (2022) 108775

enthalten in: International immunopharmacology | 2022

von Morimoto, K. | Yamada, T. | Morimoto, Y. | +9

ErratumFor: Int Immunopharmacol. 2022 Jul;108:108775. - PMID 35436741

52

Impact of maintenance therapy following induction immunochemotherapy for untreated advanced non-small cell lung cancer patients

enthalten in: Journal of cancer research and clinical oncology | 2022

von Nakamura, R. | Yamada, T. | Morimoto, K. | +17

53

Efficacy and Safety of Paclitaxel/nab-paclitaxel Chemotherapy for Patients With Relapsed Small Cell Lung Cancer

enthalten in: Anticancer research | 2022

von Matsui, Y. | Yamada, T. | Morimoto, K. | +9

54

A Real-World Analysis of Immune Checkpoint Inhibitor-Based Therapy After Osimertinib Treatment in Patients With EGFR-Mutant NSCLC

enthalten in: JTO clinical and research reports | 2022

von Morimoto, K. | Sawada, R. | Yamada, T. | +15

55

Changes in serum transforming growth factor-beta concentration as a predictive factor for radiation-induced lung injury onset in radiotherapy-treated patients with locally advanced lung cancer

enthalten in: Translational lung cancer research | 2022

von Seto, Y. | Kaneko, Y. | Mouri, T. | +6

56

Clinical impact of amrubicin monotherapy in patients with relapsed small cell lung cancer : a multicenter retrospective study

enthalten in: Translational lung cancer research | 2022

von Uda, S. | Yamada, T. | Yoshimura, A. | +25

57

Early discontinuation of induction therapy in chemoimmunotherapy as an effective alternative to the standard regimen in patients with non-small cell lung cancer : a retrospective study

enthalten in: Journal of cancer research and clinical oncology | 2022

von Morimoto, K. | Uchino, J. | Yokoi, T. | +16

58

Safety and Immunogenicity of mRNA Vaccines Against Severe Acute Respiratory Syndrome Coronavirus 2 in Patients With Lung Cancer Receiving Immune Checkpoint Inhibitors : A Multicenter Observational Study in Japan

enthalten in: Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer | 2022

von Hibino, M. | Uryu, K. | Takeda, T. | +15

59

Efficacy and Safety of Programmed Death-Ligand 1 Inhibitor Plus Platinum-Etoposide Chemotherapy in Patients With Extensive-Stage SCLC : A Prospective Observational Study

enthalten in: JTO clinical and research reports | 2022

von Morimoto, K. | Yamada, T. | Takeda, T. | +13

60

A real-world study on the safety of the extended dosing schedule for nivolumab and pembrolizumab in patients with solid tumors

enthalten in: International immunopharmacology | 2022

von Morimoto, K. | Yamada, T. | Morimoto, Y. | +9

ErratumIn: Int Immunopharmacol. 2022 Nov;112:109232. - PMID 36096994